Neurolixis Inc. has been awarded a second research grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to investigate the activity of novel serotonin 5-HT1A receptor agonists in models of Parkinson's disease.
The new one-year grant constitutes an expansion of a previous MJFF grant awarded to Neurolixis in December 2011. This generated promising results which will be presented at MJFF's 7th Annual Parkinson's Disease Therapeutics Conference in New York City on October 24, 2013, and at the Society for Neuroscience meeting in San Diego, California, in November 2013. If the new studies are successful, Neurolixis aims to take a clinical candidate, NLX-112, into proof-of-concept Phase 2 clinical trials in Parkinson's disease patients.